Leucémie lymphoïde chronique : quand débuter le traitement ?

Article Article scientifique Article Leucémie lymphoïde chronique : quand débuter le traitement ? fre 2013 author Blaser Samuel 596805 author Stirnemann Jérôme 793435 author Nagy Monika 514344 1870-1874 24298709 1660-9379 This paper reviews the literature to propose guidelines for managing patients with early-intermediate stage chronic lymphocytic leukemia (CLL). Clinical and biological parameters are sufficient to identify a cohort of patients with high-risk CLL at diagnosis who will have disease progression: anemia (Hb < 100 g/l) or thrombocytopenia (platelets < 100 G/l), bone marrow infiltration (> 30% lymphocytes), a rapid doubling time (less than 6 months) or lymphocytes above 300 g/L, splenomegaly and massive lymphadenopathy, systemic symptoms, uncontrolled autoimmune complications. Patients without those characteristics have low-risk CLL. In the absence of evidence of survival benefit in low-risk CLL, there is no indication for treatment and patients should be followed up by physical examination and complete blood count once or twice a year. Blood Cell Count/methods Disease Progression Humans Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis/pathology/therapy Neoplasm Staging Practice Guidelines as Topic Risk Survival Analysis Time Factors Dewey 618.97 65 Département de réadaptation et gériatrie 22B false 319 Groupe Perrier Arnaud (Médecine interne générale, de réhabilitation et de gériatrie) 585 Revue médicale suisse 9 402 f3a475d8-5c48-4426-84b6-ba46d4ed2638 Article (Published version) Restricted RMS_419_493.pdf 533444 application/pdf restrictedAccess Faculté de médecine / Section de médecine clinique / Département de réadaptation et gériatrie

Title	Published in	Access level	OA Policy	Year	Views	Downloads

Leucémie lymphoïde chronique : quand débuter le traitement ?	Revue médicale suisse			2013	664	1

Archive ouverte UNIGE

Blaser, Samuel